Japan’s FUJIFILM Toyama Chemical Co., Ltd announced that the company filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan® Tablet (Favipiravir) to the Ministry of Health, Labor and Welfare in Japan. The filing seeks to add an indication and other items relating to novel coronavirus infections (COVID-19). This antiviral drug, originating in Japan, has already been approved in Russia and India, at least on an emergency basis, for COVID-19.
TrialSite News has chronicled a good amount of activity associated with Favipiravir. What follows is a brief breakdown of the news, the drug and status elsewhere.
What is Avigan?
Known by the generic name Favipiravir, Avigan is already approved, since 2014, for manufacture and sale in Japan as an influenza antiviral drug as it selectively inhibits RNA polymerase necessary for influenza viral replication.
What’s the basis for pursuing approval for treating COVID-19?
As Avigan selectively inhibits viral replication it has been sought that it may have an antiviral effect on SARS-CoV-2, the virus behind COVID-19; this novel coronavirus is a RNA virus of a similar...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).